Skip to main content
S 4199 116th Congress Senate Health Accounting and auditing Administrative law and regulatory procedures Advisory bodies Appropriations Congressional oversight Department of Health and Human Services Drug safety, medical device, and laboratory regulation Drug therapy Emergency medical services and trauma care Fraud offenses and financial crimes Genetics Government information and archives Government studies and investigations Health care costs and insurance Health care coverage and access Health care quality Health information and medical records Health programs administration and funding Health technology, devices, supplies

Prescription Drug Pricing Reduction Act of 2020

Introduced: July 2, 2020 Introduced by: Grassley, Chuck Republican · Iowa See on congress.gov
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 2, 2020
Introduced in Senate
Jul 2, 2020
Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S4228)
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Prescription Drug Pricing Reduction Act of 2020

This bill alters several programs and requirements relating to the prices of prescription drugs under Medicare and Medicaid.

Among other things, the bill

  • requires drug manufacturers to issue rebates to the Centers for Medicare & Medicaid Services (CMS) for certain drugs covered under Medicare for which the average manufacturer price increases faster than inflation;
  • requires drug manufacturers to issue rebates to the CMS for discarded amounts of certain single-dose drugs covered under Medicare, based on information reported by providers;
  • reduces the annual out-of-pocket spending threshold, and eliminates beneficiary cost-sharing above this threshold, under the Medicare prescription drug benefit;
  • requires the CMS to publish certain information, as reported by pharmacy benefit managers (PBMs), relating to drug discounts and rebates, and payments between PBMs, health plans, and pharmacies;
  • requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with PBMs under Medicaid; and
  • increases the maximum rebate payable by drug manufacturers under the Medicaid Drug Rebate Program.
What's happening now July 2, 2020

Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S4228)

 Related & companion bills 11
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
Cite this page click to expand
APA
U.S. Congress. (2026). S. 4199: Prescription Drug Pricing Reduction Act of 2020. 116th Congress. Open America. https://openamerica.io/bill/116-S-4199/
MLA
"S. 4199: Prescription Drug Pricing Reduction Act of 2020." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-S-4199/.
Bluebook (legal)
S. 4199, 116th Cong. (2026), https://openamerica.io/bill/116-S-4199/.
Markdown link
[S. 4199: Prescription Drug Pricing Reduction Act of 2020](https://openamerica.io/bill/116-S-4199/)
Report a problem